tradingkey.logo
tradingkey.logo
Search

Impact Biomedical Inc

IBO
Add to Watchlist
5.140USD
+0.370+7.76%
Close 11-13 16:00(ET)
43.90MMarket Cap
LossP/E TTM
After-hours 18:30 (ET)5.140USD+0.040+0.78%

About Impact Biomedical Inc Company

Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.

Impact Biomedical Inc Profile

Ticker SymbolIBO
Company nameImpact Biomedical Inc
IPO dateSep 16, 2024
CEOHeuszel (Frank D)
Number of employees2
Security typeOrdinary Share
Fiscal year-endSep 16
Address1400 Broadfield Blvd.
CityHOUSTON
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code77084
Phone15852321500
Websitehttps://www.impactbiomedinc.com/
Ticker SymbolIBO
IPO dateSep 16, 2024
CEOHeuszel (Frank D)

Company Executives of Impact Biomedical Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Mark Suseck
Mr. Mark Suseck
Chief Operating Officer
Chief Operating Officer
27.94K
+14.92%
Dr. Elise Brownell
Dr. Elise Brownell
Independent Director
Independent Director
27.94K
+14.92%
Mr. Castel B. Hibbert
Mr. Castel B. Hibbert
Independent Director
Independent Director
27.94K
+14.92%
Mr. Jason Grady
Mr. Jason Grady
Director
Director
23.99K
+17.38%
Mr. Heng Fai (Ambrose) Chan
Mr. Heng Fai (Ambrose) Chan
Director
Director
--
--
Mr. Frank D. Heuszel, CPA
Mr. Frank D. Heuszel, CPA
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Mr. Todd D. Macko
Mr. Todd D. Macko
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Melissa Sims
Ms. Melissa Sims
Independent Director
Independent Director
--
--
Mr. David K. Keene
Mr. David K. Keene
Independent Director
Independent Director
--
--
Mr. Christian Zimmerman
Mr. Christian Zimmerman
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Mark Suseck
Mr. Mark Suseck
Chief Operating Officer
Chief Operating Officer
27.94K
+14.92%
Dr. Elise Brownell
Dr. Elise Brownell
Independent Director
Independent Director
27.94K
+14.92%
Mr. Castel B. Hibbert
Mr. Castel B. Hibbert
Independent Director
Independent Director
27.94K
+14.92%
Mr. Jason Grady
Mr. Jason Grady
Director
Director
23.99K
+17.38%
Mr. Heng Fai (Ambrose) Chan
Mr. Heng Fai (Ambrose) Chan
Director
Director
--
--
Mr. Frank D. Heuszel, CPA
Mr. Frank D. Heuszel, CPA
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--

FAQs

Who are the top five shareholders of Impact Biomedical Inc?

The top five shareholders of Impact Biomedical Inc are: Mr. Castel B. Hibbert

How many institutions hold shares of Impact Biomedical Inc (IBO)?

As of 2026Q1, 37 institutions hold shares of Impact Biomedical Inc, with a combined market value of approximately 2.77M, accounting for 2.56% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 2084658.00.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.